Although a phase III clinical trial of gp100 peptide vaccine in patients with advanced melanoma has shown encouraging results [34], most tumor-specific CD8+ T cell responses induced by vaccination have not demonstrated effective tumor regression [10]. The gene discussed is CD8A; the disease is neoplasm.